Stock Taper
LNTH
LANTHEUS HOLDINGS, INC.
NASDAQ
$100.77
▲ UP 0.30% (0.30)

KEY STATISTICS

Market Cap$6.56 B
52w High$111.86
52w Low$49.67
Dividend Yield
Frequency
P/E16.94
Volume1.14M
Shares Out.65.11M

COMPANY

LEADERSHIP

Mary Anne Heino
CHIEF EXECUTIVE
Mary Anne Heino

COMPENSATION 2026

Salary$629,230
Stock Awards$1,891,274
Incentive Plan Pay$1,173,360
All Other Comp.$13,461
Total$3,707,325

ABOUT

SECTOR
Healthcare
WENT PUBLIC
June 25, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
1,193

PRICE TARGET

Target High$120.00
Target Low$94.00
Target Median$102.50
Target Consensus$105.27

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$360.41M
NOV
5
THU

PRICE

$100.77 ▲ UP 0.30% (+$0.30)
$100$101$101$1019:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM100.77

About Lantheus Holdings, Inc.

https://www.lantheus.com ↗

Lantheus Holdings develops and markets diagnostic and therapeutic medical products, including imaging agents, radiotherapeutics, and AI software, serving healthcare providers worldwide to diagnose and treat various diseases.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT LANTHEUS HOLDINGS, INC. IS KNOWN FOR

PYLARIFY® (piflufolastat F 18) injection
PYLARIFY® (piflufolastat F 18) injection

PYLARIFY is Lantheus's top-selling, blockbuster PET imaging agent for prostate cancer, exceeding $1 billion in 2024, and is the first radiodiagnostic of its kind targeting PSMA-positive lesions.

COMPETITORS

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$376.69M $389.42M $369.85M $376.93M
Oncology$240.92M $240.37M
PYLARIFY$240.62M $240.2M $240.92M $240.37M
Radiopharmaceutical Oncology$240.62M $240.2M
Total Precision Diagnostics$129.69M $143.25M
Cardiology$84.63M $88.28M
DEFINITY$81.78M $85.31M $84.63M $88.28M
Techne Lite$21.13M $20.98M
Strategic Partnerships And Other$13.71M $23.34M $16.34M $19.92M
License and Royalty Revenues$7.33M $17.36M $7.48M $11.25M
Other Precision Diagnostics$6.34M $5.94M

Revenue by Geography

MapREGIONQ1-2026Q2-2026
UNITED STATES$354.43M $368.29M
NonUS$22.91M $19.89M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity5
Return On Assets5
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score3

INSIDER TRADES

OFFICER: SEE REMARKS
Dinkelborg Ludger
Sale · 2.5K shares
2026-08-17
OFFICER: CHIEF ACCOUNTING OFFICER
Brown Kimberly
Sale · 463 shares
2026-08-17
DIRECTOR
McHugh Julie
Purchase · 4.1K shares
2026-05-14
DIRECTOR
Morrow Phuong Khanh
Purchase · 4.1K shares
2026-05-14

MOST RECENT ANALYST GRADES

GRADE SUMMARY
HOLD 3
MARKET PERFORM 2
OUTPERFORM 1
BUY 1
MARKET OUTPERFORM 1
NEUTRAL 1
9 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
HNGE$87.35COMPARE
AMRX$17.54COMPARE
ACAD$29.11COMPARE
INDV$34.87COMPARE
SUPN$43.73COMPARE
BHC$6.32COMPARE